Trial Profile
An Observational Study for Safety and Efficacy of Erlotinib Beyond 1st Line in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2014
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Oct 2013 New trial record